Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (10951)	11/12/1997 8:30:00 AM
From: Henry Niman	Respond to of 32384

Andy, Here's a brief article that appeared in San Diego's business publication, the Daily Transcript, a couple of weeks ago. As noted previously, LGND expects to file an NDA for oral and topical Targretin the the second half of next year: Ligand Data San Diego-based Ligand Pharmaceuticals Inc. has reported that clinical data for its Targretin capsules, designed to treat cutaneous T-cell lymphoma, are "favorable." Company officials said patients who had been refractory or intolerant to prior therapy "achieved a complete or partial response" from dosages of Targretin capsules. According to the company, out of 21 patients with advanced stage CTCL who received a higher dose of Targretin capsules, 43 percent showed complete or partial response and 33 percent achieved stabilization of disease. Ligand anticipates filing new drug applications for Targretin Capsules and Topical Gel in the second half of 1998.

To: Andrew H who wrote (10951)	11/12/1997 8:33:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Andy, Early last month the Daily Transcript also put out a summary of the oral Panretin treatment of APL: Allergan Trials Allergan Ligand Retinoid Therapeutics announced that leukemia patients participating in a clinical trial of oral Panretin attained complete durable remissions. The trial included 18 patients who were treated with a once-daily dose of the drug. Of the 18 patients, five were newly diagnosed and 13 were relapsed from previous therapy. Four of five newly diagnosed patients attained complete remission. The trail was conducted in the U.S. Allergan Ligand is a San Diego-based joint venture between Ligand Pharmaceuticals and Orange County-based Allergan.